Roche Holding Ltd (RHHBY)

[pointofreturn]

With Patent Cliff Looming, 2 Potential Takeover Targets For Roche

What Can Roche Do About The Expiration?
One way to offset the risk of a patent cliff is to extend the life of the expiring drug through modification. Modification might involve combining a drug with another compound to improve efficacy, or simply altering the delivery of the drug. There are problems associated with these actions however. Conducting trials to seek enhanced efficacy can be costly and time consuming; further, there is no guarantee that a combination will be successful. Altering the delivery method necessitates improved release rates, which even if achieved offer no guarantee of approval and extended exclusivity.

Read more:
http://www.investing.com/analysis/with-patent-cliff-looming,-2-potential-takeover-targets-for-roche-204220

Theralese Technologies Inc. (TLTFF): Potential Target Number One

The first company that could be the target of a Roche deal in the next two years is Theralase, Inc. (TLT.V) (TLTFF). Theralase currently generates revenues from the sale of its cold laser technology, which practitioners use to simulate the healing process in patients with muscle damage. In addition to this however, Theralase is currently developing a type of cancer treatment, which uses lasers to activate compounds that, when activated, kill cancer cells.


Theralase (TLTFF) : A Prime Roche Target
Just found this article about a big pharma company, Roche, and two potential targets for it to acquire based on its 'patent cliff', particularly its expiring Herceptin sales...


A patent cliff is the decline in revenues a pharmaceutical company experiences when the patents on one or more of their protected compounds expires. The lack of patent protection opens up the market to generic alternatives, which generic drug manufacturers sell at a discount to the branded option. This reduced cost redirects revenues from the manufacturers (generally big pharma) that bore the cost of research and development.

During 2014, the patent cliff concept will expose a number of incumbent pharmaceutical companies to potential revenue redirection. One of those companies is Roche Holdings (RHHBY), with the European patent for the company's breast cancer drug, Herceptin, due for expiry. Roche's Herceptin sales totaled $6.07B during 2013, 16% of the company's total annual sales.

Source:
http://www.investing.com/analysis/with-patent-cliff-looming,-2-potential-takeover-targets-for-roche-204220